オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 3000 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 2000 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 1000 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 500 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 250 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 3000 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 2500 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 2000 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 1500 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 1000 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.